dc.contributor.author | Sengul, Aysun | |
dc.contributor.author | Mutlu, Pinar | |
dc.contributor.author | Ozdemir, Ozer | |
dc.contributor.author | Satici, Celal | |
dc.contributor.author | Turan, Muzaffer Onur | |
dc.contributor.author | Arslan, Sertac | |
dc.contributor.author | Ogang, Nalan | |
dc.date.accessioned | 2023-11-16T18:30:05Z | |
dc.date.available | 2023-11-16T18:30:05Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 1747-6348 | |
dc.identifier.issn | 1747-6356 | |
dc.identifier.uri | https://doi.org/10.1080/17476348.2022.2102480 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14065/5575 | |
dc.description.abstract | Background COVID-19 is a disease associated with diffuse lung injury that has no proven effective treatment yet. It is thought that glucocorticoids may reduce inflammation-mediated lung injury, disease progression, and mortality. We aimed to evaluate our patient's characteristics and treatment outcomes who received corticosteroids for COVID-19 pneumonia. Methods We conducted a multicenter retrospective study and reviewed 517 patients admitted due to COVID-19 pneumonia who were hypoxemic and administered steroids regarding demographic, laboratory, and radiological characteristics, treatment response, and mortality-associated factors. Results Of our 517 patients with COVID-19 pneumonia who were hypoxemic and received corticosteroids, the mortality rate was 24.4% (n = 126). The evaluation of mortality-associated factors revealed that age, comorbidities, a CURB-65 score of >= 2, higher SOFA scores, presence of MAS, high doses of steroids, type of steroids, COVID-19 treatment, stay in the intensive care unit, high levels of d-dimer, CRP, ferritin, and troponin, and renal dysfunction were associated with mortality. Conclusion Due to high starting and average steroid doses are more associated with mortality, high-dose steroid administration should be avoided. We believe that knowing the factors associated with mortality in these cases is essential for close follow-up. The use of CURB-65 and SOFA scores can predict prognosis in COVID-19 pneumonia. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Taylor & Francis Ltd | en_US |
dc.relation.ispartof | Expert Review of Respiratory Medicine | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Covid-19 | en_US |
dc.subject | Corticosteroid | en_US |
dc.subject | Hypoxemia | en_US |
dc.subject | Mortality | en_US |
dc.subject | Prognosis | en_US |
dc.subject | Respiratory-Distress-Syndrome | en_US |
dc.subject | Dexamethasone | en_US |
dc.subject | Severity | en_US |
dc.title | Characteristics of our hypoxemic COVID-19 pneumonia patients receiving corticosteroids and mortality-associated factors | en_US |
dc.type | article | en_US |
dc.authorid | Aydemir, Yusuf/0000-0003-2479-2949 | |
dc.authorid | Söyler, Yasemin/0000-0002-0507-0767 | |
dc.authorid | Sengul, Aysun/0000-0002-8084-1322 | |
dc.authorid | Ozdemir, Ozer/0000-0002-8884-0682 | |
dc.department | Ufuk Üniversitesi | en_US |
dc.identifier.doi | 10.1080/17476348.2022.2102480 | |
dc.identifier.volume | 16 | en_US |
dc.identifier.issue | 8 | en_US |
dc.identifier.startpage | 953 | en_US |
dc.identifier.endpage | 958 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.authorwosid | Yildirim, Fatma/AET-5783-2022 | |
dc.authorwosid | Aydemir, Yusuf/F-7334-2019 | |
dc.authorwosid | Söyler, Yasemin/AAF-8533-2021 | |
dc.authorwosid | turan, pakize ayşe/JJC-3826-2023 | |
dc.identifier.wos | WOS:000831157700001 | en_US |
dc.identifier.scopus | 2-s2.0-85135114550 | en_US |
dc.identifier.pmid | 35839345 | en_US |